AGC to use re­cent­ly-ex­pand­ed Ger­many site for peanut al­ler­gy drug tri­als

Those who are al­ler­gic to peanut but­ter: re­joice. Al­ler­gy Ther­a­peu­tics’ virus-like par­ti­cle peanuts al­ler­gy can­di­date is about to en­ter Phase I tri­als, and the com­pa­ny has se­lect­ed AGC Bi­o­log­ics to take on man­u­fac­tur­ing du­ties.

AGC will pro­vide VLP ma­te­r­i­al for Al­ler­gy’s Phase I sup­ply. The biotech just land­ed an IND from the FDA, which in­clud­ed da­ta from the team’s col­lab­o­ra­tion, and now has a clear path for a Phase I tri­al in the US that will be­gin lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER